Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?

Conclusions and Future Directions Practicing rheumatologists in Latin America need to understand the regulatory situation for biosimilars in their countries. When considering bDMARDs that are not innovator products, clinicians should use only those that have been approved according to the WHO recommendations. For clarification, local health authorities or professional associations should be contacted.
Source: JCR: Journal of Clinical Rheumatology - Category: Rheumatology Tags: Review Source Type: research